tbuckley/cabot-search huggingface dataset:
Abstract 17189: Prevalence and Relevance of Recurrent Premature Ventricular Complexes in the Pre-discharge Period Following Pvc Ablation
Authors: Sanghamitra Mohanty, John David Burkhardt, Chintan Trivedi, Carola Gianni, Mahmut F Gunes, Yalcin Gokoglan, Amin Al-Ahmad, Javier Sanchez, Patrick Hranitzky, G. J Gallinghouse, Rodney Horton, Luigi Di Biase, Andrea Natale
Journal: Circulation (2015)

Background: Radiofrequency catheter ablation is widely-used to target frequent premature ventricular complexes (PVCs) in patients with and without structural heart disease, with reported ablation-success rate being in the 80% range. However the risk-factors that correlate with ablation-failure have not been defined yet. We aimed to assess the prevalence of recurrent PVCs in the immediate post-ablation period and their relevance in relation to the clinical outcome of catheter ablation of PVCs. Methods: A consecutive series of 104 patients (age: 58±15 years, male 57%, LVEF 54±10.8) with frequent PVCs and without structural heart disease referred for catheter ablation at our center, were included in this prospective analysis. Successful ablation was defined as the absence of spontaneous or induced clinical PVC, both with or without isoproterenol at the end of the procedure. Arrhythmia burden was assessed at baseline and follow-up using 24-hour Holter recording. Telemetry was performed for at least 12 hours in the immediate post-ablation period. Ablation success was defined as ≥ 90% reduction of the initial PVC burden at 3-month follow-up. Results: At baseline, the mean number of PVC morphologies was 1.4± 2.2 and the predominant PVCs commonly originated from right ventricular outflow tract [34 (32.6%)], coronary cusps [28 (27%)], interventricular septum [16 (15.3%)] and left ventricular outflow tract [13 (12.5%)]. Elimination of predominant PVCs was achieved in all patients. In the 12-hour post-ablation period, recurrence of PVCs was observed in 16 (15%) patients, which were transitory and never documented at follow-up monitoring. The most common sites of origin of these early PVCs were anterior cardiac veins, papillary muscles and mitral valve annulus. At follow-up, recurrence was reported in 5 of the 104 patients (4.8%) of which only one had early PVCs during the 12-hour post-ablation period. Conclusions: Recurrence of PVCs in the immediate post-ablation period is transient and not indicative of the failure of the index procedure. Furthermore, pre-discharge PVCs do not demonstrate any definite correlation with the risk of late recurrence. This is most likely the result of myocardial irritation secondary to the trauma of the ablation procedure.
Prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) treatment in patients (pts) with advanced gastrointestinal stromal tumor (GIST)
Authors: H. Cho, M.-H. Ryu, H. Chae, S.M. Lee, Y. Park, K.-H. Kim, C.W. Kim, B.S. Kim, M.-W. Yoo, J. Ma, M.Y. Beck, M. Kim, Y.-K. Kang
Journal: Annals of Oncology (2018)
Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies
Authors: Fumiaki Imamura, Amanda Fretts, Matti Marklund, Andres V. Ardisson Korat, Wei-Sin Yang, Maria Lankinen, Waqas Qureshi, Catherine Helmer, Tzu-An Chen, Kerry Wong, Julie K. Bassett, Rachel Murphy, Nathan Tintle, Chaoyu Ian Yu, Ingeborg A. Brouwer, Kuo-Liong Chien, Alexis C. Frazier-Wood, Liana C. del Gobbo, Luc Djoussé, Johanna M. Geleijnse, Graham G. Giles, Janette de Goede, Vilmundur Gudnason, William S. Harris, Allison Hodge, Frank Hu, Albert Koulman, Markku Laakso, Lars Lind, Hung-Ju Lin, Barbara McKnight, Kalina Rajaobelina, Ulf Risérus, Jennifer G. Robinson, Cécilia Samieri, David S. Siscovick, Sabita S. Soedamah-Muthu, Nona Sotoodehnia, Qi Sun, Michael Y. Tsai, Matti Uusitupa, Lynne E. Wagenknecht, Nick J. Wareham, Jason HY Wu, Renata Micha, Nita G. Forouhi, Rozenn N. Lemaitre, Dariush Mozaffarian
Journal: PLoS Medicine (2018)

We aimed to investigate prospective associations of circulating or adipose tissue odd-chain fatty acids 15:0 and 17:0 and trans-palmitoleic acid, t16:1n-7, as potential biomarkers of dairy fat intake, with incident type 2 diabetes (T2D).
Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
Authors: C. Suarez, T.K. Choueiri, D.F. McDermott, B. Escudier, M.B. Atkins, T.B. Powles, B.I. Rini, R.J. Motzer, S.K. Pal, L. Fong, U. De Giorgi, Y. Wang, T. Khaznadar, F. Di Nucci, C. Kaiser, D. Tayama, F. Donskov
Journal: Annals of Oncology (2018)
Intestinal hyperpermeability: a gateway to multi-organ failure?
Authors: QiQi Zhou, G. Nicholas Verne
Journal: Journal of Clinical Investigation (2018)

In critically ill patients, disruption of intestinal epithelial cell function occurs due to exposure of the epithelium to toxic internal and external inflammatory stimuli, which are key factors that trigger sepsis and multi-organ dysfunction syndrome (MODS). A greater understanding of how trauma and gut failure lead to sepsis and progression to MODS is much needed. In this issue of the JCI, Armacki and colleagues identify mechanisms by which thirty-eight-negative kinase 1 (TNK1) promotes the progression from intestinal apoptosis and gut failure to bacterial translocation, sepsis, and MODS. Moreover, the results of this study suggest TNK1 as a potential therapeutic target to prevent sepsis and MODS.
Sixty seconds on . . . shared appointments
Authors: Susan Mayor
Journal: BMJ (2018)

You may think so from last week’s Daily Telegraph 1 headline which screamed: “GPs to see patients in groups of 15.” In fact, the newspaper was reporting a discussion about shared appointments at the recent Royal College of General Practitioners conference.

Patients attending shared appointments usually share a key attribute, typically their medical condition. Appointments last around 90 minutes and involve a multidisciplinary …
GW29-e1357 A Risk Model to Predict One-Year Mortality at Hospital Discharge in Acute Coronary Syndromes Patients
Authors: Xin Du, Yingxue Li, Tiange Chen, Xiang Li, Xuedan You, Xianhong Wang, Lu Bai, Yong Qin, Changsheng Ma, Xin Du
Journal: Journal of the American College of Cardiology (2018)
Complete Versus Culprit-Only Lesion Intervention in Patients With Acute Coronary Syndromes
Authors: Krishnaraj S. Rathod, Sudheer Koganti, Ajay K. Jain, Zoe Astroulakis, Pitt Lim, Roby Rakhit, Sundeep Singh Kalra, Miles C. Dalby, Constantinos O’Mahony, Iqbal S. Malik, Charles J. Knight, Anthony Mathur, Simon Redwood, Alexander Sirker, Philip A. MacCarthy, Elliot J. Smith, Andrew Wragg, Daniel A. Jones
Journal: Journal of the American College of Cardiology (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Authors: Linda M Henricks, Carin A T C Lunenburg, Femke M de Man, Didier Meulendijks, Geert W J Frederix, Emma Kienhuis, Geert-Jan Creemers, Arnold Baars, Vincent O Dezentjé, Alexander L T Imholz, Frank J F Jeurissen, Johanna E A Portielje, Rob L H Jansen, Paul Hamberg, Albert J ten Tije, Helga J Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H W van de Poel, Caroline M P W Mandigers, Hilde Rosing, Jos H Beijnen, Erik van Werkhoven, André B P van Kuilenburg, Ron H N van Schaik, Ron H J Mathijssen, Jesse J Swen, Hans Gelderblom, Annemieke Cats, Henk-Jan Guchelaar, Jan H M Schellens
Journal: The Lancet Oncology (2018)
Insights into imprinting from parent-of-origin phased methylomes and transcriptomes
Authors: Florian Zink, Droplaug N. Magnusdottir, Olafur T. Magnusson, Nicolas J. Walker, Tiffany J. Morris, Asgeir Sigurdsson, Gisli H. Halldorsson, Sigurjon A. Gudjonsson, Pall Melsted, Helga Ingimundardottir, Snædis Kristmundsdottir, Kristjan F. Alexandersson, Anna Helgadottir, Julius Gudmundsson, Thorunn Rafnar, Ingileif Jonsdottir, Hilma Holm, Gudmundur Ingi Eyjolfsson, Olof Sigurdardottir, Isleifur Olafsson, Gisli Masson, Daniel F. Gudbjartsson, Unnur Thorsteinsdottir, Bjarni V. Halldorsson, Simon N. Stacey, Kari Stefansson
Journal: Nature Genetics (2018)
SAT0261 Certolizumab pegol serum levels ≥20 mg/l are associated with treatment response in patients with axial spondyloarthritis. data from the nor-dmard study
Authors: J.E. Gehin, S.W. Syversen, D.J. Warren, G.L. Goll, J. Sexton, E.K. Strand, T.K. Kvien, N. Bolstad, E. Lie
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors. An association between certolizumab pegol (CP) serum levels and response has previously been found in patients (pts) with rheumatoid arthritis.<sup>1</sup> Data for pts with axial spondyloarthritis (axSpA) are lacking. <h3>Objectives</h3> To examine the association between serum CP levels and treatment response in pts with axSpA and to identify a therapeutic target level. <h3>Methods</h3> Patients with a clinical diagnosis of axSpA starting standard treatment with CP included in the NOR-DMARD study with biobank sample at 3 months follow-up, were included in the present analyses. Serum drug levels (non-trough) were analysed with an in-house immunofluorometric assay automated on the AutoDELFIA immunoassay platform. Associations between CP level and improvement in ASDAS-CRP and response (defined as ASDAS clinically important improvement (CII)) were assessed by multivariable linear and logistic regression (adjusting for age, sex and prior bDMARD (Y/N)), respectively. <h3>Results</h3> Median serum drug level at 3 month follow up was 35.0 mg/L (IQR 21.3–45.3) in 116 pts. Response data were available in 110/116 patients. Serum CP level ≥20 mg/L was associated with improvement in ASDAS at 3 months (β=0.55, (95% CI 0.12–1.98), p=0.01). Serum CP level ≥20 mg/L was associated with ASDAS CII at 3 months (OR 3.4 (95% CI 1.0–11.1, p=0.045)). Only 18.2% of pts with CP level &lt;20 mg/L achieved ASDAS CII at 3 months, while 53.2% of pts with CP level 20–40 mg/L and 36.6% with ≥40 mg/L were responders. <h3>Conclusions</h3> Serum CP level was associated with clinical response after 3 months of treatment in pts with axSpA. We suggest 20 mg/L as a lower target level for non-trough samples. No additional benefit of having a certolizumab level over 40 mg/L was observed. These results suggest that a therapeutic level of 20–40 mg/L can be implemented in clinical practice for non-trough serum samples in pts with axSpA. <h3>Reference</h3> [1] Jani M, et al. Ann Rheum Dis2017;76(1):208–13. <h3>Disclosure of Interest</h3> J. E. Gehin Consultant for: Roche, S. Syversen Consultant for: Roche, D. Warren: None declared, G. Goll Consultant for: Abbvie, Biogen, Boehringer Ingelheim, Orion Pharma, Eli Lilly, Novartis, Pfizer, MSD, Roche, UCB, J. Sexton: None declared, E. Strand Consultant for: Pfizer, T. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, UCB, N. Bolstad Consultant for: Pfizer, Orion Pharma, Napp pharmaceuticals, Takeda, Roche, E. Lie: None declared
Incidence of immune related adverse events in patients 70 years old treated with anti-PD-(L)1 therapy
Authors: C. Baldini, P. Martin-Romano, A.-L. Voisin, F.X. Danlos, S. Champiat, S. Laghouati, M. Kfouri, H. Vincent, C. Nagera, S. Postel-Vinay, A. Varga, V. Ribrag, B. Besse, A. Hollebecque, O. Lambotte, J.-M. Michot, J.-C. Soria, C. Massard, A. Marabelle
Journal: Annals of Oncology (2018)
Overexpression of NAMPT in adult T-cell leukemia/lymphoma patients and anti-tumor activity of a NAMPT inhibitor in vivo
Authors: T. Kozako, T. Ohsugi, M. Yoshimitsu, Y.-I. Uchida, K. Ishitsuka, K. Naho, A. Aikawa, S.-I. Honda
Journal: Annals of Oncology (2018)

Background: Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature T lymphocytes induced by human T-cell leukemia virus (HTLV) that has poor outcomes. New molecular targets for prevention and treatment of ATL are urgently needed. We reported that SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent histone/protein deacetylase, is highly expressed in primary acute-type ATL cells. NAD+ biosynthesis via nicotinamide phosphoribosyltransferase (NAMPT) modulates SIRT1 activity. We examined the expression and inhibition of NAMPT, a rate-limiting enzyme in NAD+ biosynthesis, in ATL cells. Methods: Peripheral blood mononuclear cells from ATL patients were carried out in accordance with the guidelines of the Committees for Ethical Review of Research involving Human Subjects at Kagoshima University Hospital. Cell viability was evaluated in the S1T cell line derived from an ATL patient, MT-2 cell line derived from normal human leukocytes transformed by leukemic T-cells from an ATL patient, and primary ATL cells. Animal experiments were approved by the Animal Care and Use Committee of Rakuno Gakuen University in accordance with the Guide for the Care and Use of Laboratory Animals. Results: Peripheral blood mononuclear cells from acute-type ATL patients expressed significantly higher NAMPT protein levels than cells from healthy controls. FK866, a NAMPT inhibitor, induced apoptosis in cell lines and fresh ATL cells, accompanied by caspase activation, DNA fragmentation, and mitochondrial transmembrane potential disruption in vitro. A pan-caspase inhibitor failed to prevent the FK866-induced cell death, while FK866 increased endonuclease G, a caspase-independent cell death mediator. Intriguingly, FK866 activated autophagy, revealed by increased LC3-II protein levels. Thus, FK866 simultaneously activated apoptosis and autophagy. Finally, FK866 treatment markedly decreased human ATL tumor xenograft growth in immunodeficient mice. Conclusions: These results demonstrate that NAMPT inhibition induces autophagy and caspase-dependent and -independent cell death in ATL cells, suggesting a novel therapeutic strategy for patients with this fatal disease. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line
Authors: N. Matrone, A. Chambery, R. Russo, P.V. Pedone, V. Belli, S. Napolitano, E. Martinelli, E.F. Giunta, V. De Falco, N. Zanaletti, P. Vitale, M. Terminiello, C. Cardone, F. Ciardiello, T. Troiani
Journal: Annals of Oncology (2018)
Cost-Effectiveness Analysis of Adalimumab for the Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis
Authors: Dyfrig A. Hughes, Giovanna Culeddu, Catrin O. Plumpton, Eifiona Wood, Andrew D. Dick, Ashley P. Jones, Andrew McKay, Paula R. Williamson, Sandrine Compeyrot Lacassagne, Ben Hardwick, Helen Hickey, Patricia Woo, Michael W. Beresford, Athimalaipet V. Ramanan
Journal: Ophthalmology (2018)
Association of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in <i>ApoE4</i> Carriers
Authors: Qiushan Tao, Ting Fang Alvin Ang, Charles DeCarli, Sanford H. Auerbach, Sheral Devine, Thor D. Stein, Xiaoling Zhang, Joseph Massaro, Rhoda Au, Wei Qiao Qiu
Journal: JAMA Network Open (2018)

The association between peripheral inflammatory biomarkers and Alzheimer disease (AD) is not consistent in the literature. It is possible that chronic inflammation, rather than 1 episode of inflammation, interacts with genetic vulnerability to increase the risk for AD.To study the interaction between the apolipoprotein E (ApoE) genotype and chronic low-grade inflammation and its association with the incidence of AD.In this cohort study, data from 2656 members of the Framingham Heart Study offspring cohort (Generation 2; August 13, 1971-November 27, 2017) were evaluated, including longitudinal measures of serum C-reactive protein (CRP), diagnoses of incident dementia including AD, and brain volume. Chronic low-grade inflammation was defined as having CRP at a high cutoff level at a minimum of 2 time points. Statistical analysis was performed from December 1, 1979, to December 31, 2015.Development of AD and brain volumes.Of the 3130 eligible participants, 2656 (84.9%; 1227 men and 1429 women; mean [SD] age at last CRP measurement, 61.6 [9.5] years) with both ApoE status and longitudinal CRP measurements were included in this study analysis. Median (interquartile range) CRP levels increased with mean (SD) age (43.3 [9.6] years, 0.95 mg/L [0.40-2.35 mg/L] vs 59.1 [9.6] years, 2.04 mg/L [0.93-4.75 mg/L] vs 61.6 [9.5] years, 2.21 mg/L [1.05-5.12 mg/L]; P < .001), but less so among those with ApoE4 alleles, followed by ApoE3 then ApoE2 genotypes. During the 17 years of follow-up, 194 individuals (7.3%) developed dementia, 152 (78.4%) of whom had AD. ApoE4 coupled with chronic low-grade inflammation, defined as a CRP level of 8 mg/L or higher, was associated with an increased risk of AD, especially in the absence of cardiovascular diseases (hazard ratio, 6.63; 95% CI, 1.80-24.50; P = .005), as well as an increased risk of earlier disease onset compared with ApoE4 carriers without chronic inflammation (hazard ratio, 3.52; 95% CI, 1.27-9.75; P = .009). This phenomenon was not observed among ApoE3 and ApoE2 carriers with chronic low-grade inflammation. Finally, a subset of 1761 individuals (66.3%) underwent brain magnetic resonance imaging, and the interaction between ApoE4 and chronic low-grade inflammation was associated with brain atrophy in the temporal lobe (β = -0.88, SE = 0.22; P < .001) and hippocampus (β = -0.04, SE = 0.01; P = .005), after adjusting for confounders.In this study, peripheral chronic low-grade inflammation in participants with ApoE4 was associated with shortened latency for onset of AD. Rigorously treating chronic systemic inflammation based on genetic risk could be effective for the prevention and intervention of AD.
Mumps Outbreak in a Marshallese Community — Denver Metropolitan Area, Colorado, 2016–2017
Authors: Grace E. Marx, Alexis Burakoff, Meghan Barnes, Donna Hite, Amanda Metz, Karen Miller, Emily Spence Davizon, Jennifer Chase, Carol McDonald, Maggie McClean, Lisa Miller, Bernadette A. Albanese
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

In January 2017, the Colorado Department of Public Health and Environment (CDPHE) identified four epidemiologically linked cases of mumps among persons from a Marshallese community who were members of the same church in the Denver metropolitan area. During 2016-2017, sizable outbreaks of mumps reported in Arkansas, Hawaii, and Washington also affected the Marshallese population (1). CDPHE, the Tri-County Health Department (TCHD), and Denver Public Health collaborated to conduct an outbreak investigation during January-March 2017 using active and passive surveillance that identified 17 confirmed and 30 probable cases. Public health actions included conducting measles-mumps-rubella (MMR) vaccination clinics at local Marshallese churches; these resulted in the vaccination of 126 persons with ≥1 doses of MMR vaccine. Implementation of active surveillance and support from local Marshallese church leaders in promoting vaccination programs likely contributed to interruption of the outbreak.
Q-TWiST analysis to assess benefit-risk of pembrolizumab in patients with PD-L1-positive advanced or metastatic NSCLC
Authors: M. Huang, M.C. Pietanza, A. Samkari, J. Pellissier, T. Burke, S. Chandwani, F. Kong, A.S. Pickard
Journal: Annals of Oncology (2018)
Vemurafenib in patients (pts) harboring BRAF V600 mutation: Results of non-small cell lung cancer (NSCLC) cohort from the AcSé trial
Authors: J. Mazières, L. Montané, F. Barlesi, X. Quantin, J. Trédaniel, J. Le Treut, V. Avrillon, A. Lavolé, V. Westeel, F. Orsini Piocelle, E. Pichon, L. Thiberville, C. Borel, P.A. Renault, M. Jaffro, S. Collot, G. Ferretti, F. Legrand, C. Mahier Ait Oukhatar, J.Y. Blay
Journal: Annals of Oncology (2018)
Lifestyles and mindsets of Olympic, Paralympic and world champions: is an integrated approach the key to elite performance?
Authors: Lauren Burns, Juanita Ruth Weissensteiner, Marc Cohen
Journal: British Journal of Sports Medicine (2018)

Objectives The holy grail of any nation in the global sporting race is to better understand, replicate and sustain podium winning performances on the world stage. International sporting bodies advocate a holistic approach to the athletic profile and environmental and system-level factors required for world-class sporting performance, yet key lifestyle, relational, training and performance practices are commonly overlooked. We aimed to explore the contribution, interplay, and impact of lifestyle and psychological factors among a sample of world-class, champion athletes. Methods Open-ended, semistructured face-to-face interviews were conducted with 10 World, Olympic and Paralympic Champion athletes that covered their sporting development and athletic profile including their mindset, training and competition practices, along with lifestyle and other key factors to which they attributed their success. A thematic approach guided by grounded theory principles, was employed to source and analyse their perspectives and experiences and determine common themes. Results Four dominant and overlapping themes emerged: psychological attributes, interpersonal relationships, performance strategies and lifestyle practices. All athletes attributed their success to psychological rather than physical factors, and the vast majority relied on mental rehearsal skills and recovery practices. Conclusion The athletic profile and support required to reach and sustain podium-level performance is multidimensional, integrated and individualised and psychological factors are paramount. Championship performance is likely to occur at the intersection of psychological prowess, interpersonal support, effective performance strategies and lifestyle. An integrated approach inclusive of these dimensions can be used to guide athlete development and support at both an individual level and a collective level.
PTH-076 Severity of bile acid malabsorption correlates with length of ileal resection in crohn’s disease
Authors: T Skouras, Y Prasad, S Dodd, S Subramanian
Journal: Gut (2017)

Introduction  Bile acid malabsorption (BAM) is a common cause of diarrhoea in Crohn’s disease (CD) patients with ileal resection and can lead to complications such as renal and biliary stone disease. BAM is usually diagnosed by selenium labelled homo-taurocholic acid test (75SeHCAT) but its availability is limited. Thus, a large proportion of resected CD patients either remain underdiagnosed or subject to empirical therapy. There is a paucity of studies examining the correlation between length of ileal resection and severity of BAM which will be of particular use to clinicians with no recourse to diagnostic testing for BAM.  Method  We identified all CD patients with a prior surgical resection who underwent 75SeHCAT testing at our institute. Testing was based on the treating clinician’s discretion. The length of resected ileum was recorded from histopathology report. We conducted a Spearman’s correlation test to check for correlation between length of resected ileum and percentage retention on 75SeHCAT. Response to treatment with bile salt sequestrant and 75SeHCAT retention values was tested using Mann-Whitney test.  Results  A total of 97 patients were identified with a mean age of 46.4 (SD 14.5). The median length of resected ileum was 22.5 cms (range 1.5–95 cms) with a median of 1 resection (range 1–4). Overall, 90 patients (92.8%) had 75SeHCAT retention values of  15%. There was moderate correlation between 75SeHCAT retention and length of ileal resection (Spearman’s rho: 0.4041, p  Conclusion  There was moderate correlation between length of ileal resection and severity of BAM as defined by 75SeHCAT retention values. Response to bile salt sequestrant therapy was not dependent on 75SeHCAT retention values.  Disclosure of Interest  None Declared